Utilization Management

Prior Authorization and Step Therapy Policies for Commercial and Individual Family Business

Oncology - Retevmo PA Policy Policy
Oncology - Revlimid PA Policy Policy
Oncology - Revuforj PA Policy
Oncology - Romvimza PA Policy
Oncology - Rozlytrek PA Policy Policy
Oncology - Sorafenib PA Policy
Oncology - Sprycel PA Policy Policy
Oncology - Stivarga PA Policy Policy
Oncology - Sunitinib PA Policy Policy
Oncology - Tabrecta PA Policy Policy
Oncology - Tagrisso PA Policy Policy
Oncology - Tasigna (Nilotinib Products) PA Policy
Oncology - Tazverik PA Policy Policy
Oncology - Temozolomide Capsules PA Policy Policy
Oncology - Truqap PA Policy
Oncology - Tukysa PA Policy Policy
Oncology - Turalio PA Policy Policy
Oncology - Ukoniq PA Policy Policy
Oncology - Valchlor PA Policy Policy
Oncology - Venclexta PA Policy Policy
Oncology - Vistogard PA Policy Policy
Oncology - Vitrakvi PA Policy Policy
Oncology - Vizimpro PA Policy Policy
Oncology - Vonjo PA Policy
Oncology - Voranigo PA Policy
Oncology - Xermelo PA Policy Policy
Oncology - Zolinza PA Policy Policy
Oncology - Zydelig PA Policy Policy
Oncology (Injectable - Bispecific - BCMA-Directed) - Elrexfio PA Policy
Oncology (Injectable - Bispecific - BCMA-Directed) - Tecvayli PA Policy
Oncology (Injectable - Bispecific - CD20-Directed) - Lunsumio PA Policy
Oncology (Injectable - Bispecific - GPRC5D-Directed) - Talvey PA Policy
Oncology (Injectable - CTLA-4 Antibody) - Imjudo PA Policy
Oncology (Injectable - Programmed Death Receptor-1) - Opdualag PA Policy
Oncology (Injectable - Programmed Death Receptor-1) - Tevimbra PA Policy
Oncology (Injectable - Programmed Death Receptor-1) - Zynyz PA Policy
Oncology (Injectable - Programmed Death-Ligand 1) - Tecentriq Hybreza PA Policy
Oncology (Injectable) - Amtagvi PA Policy
Oncology (Injectable) - Besremi PA Policy
Oncology (Injectable) - Columvi PA Policy
Oncology (Injectable) - Epkinly PA Policy
Oncology (Injectable) - Gonadotropin-Releasing Hormone Analogs PA Policy Policy
Oncology (Injectable) - Gonadotropin-Releasing Hormone Analogs PSM policy Policy
Oncology (Injectable) - Synribo PA Policy Policy
Oncology (Injectable) - Tecelra PA Policy
Oncology (Intravesical) - Adstiladrin PA Policy
Oncology (Intravesical) - Anktiva PA Policy
Oncology (Oral - Anaplastic Lymphoma Kinase [ALK]-Positive Agent) - Alecensa PA Policy
Oncology (Oral - Anaplastic Lymphoma Kinase [ALK]-Positive Agent) - Alunbrig PA Policy
Oncology (Oral - Anaplastic Lymphoma Kinase [ALK]-Positive Agent) - Lorbrena PA Policy
Oncology (Oral - Anaplastic Lymphoma Kinase [ALK]-Positive Agent) - Xalkori PA Policy
Oncology (Oral - Anaplastic Lymphoma Kinase [ALK]-Positive Agent) - Zykadia PA Policy
Oncology (Oral - Androgen Biosynthesis Inhibitor) - Abiraterone Acetate PA Policy
Oncology (Oral - Androgen Biosynthesis Inhibitor) - Yonsa PA Policy
Oncology (Oral - Androgen Receptor Inhibitor) - Erleada PA Policy
Oncology (Oral - Androgen Receptor Inhibitor) - Nubeqa PA Policy
Oncology (Oral - Androgen Receptor Inhibitor) - Xtandi PA Policy
Oncology (Oral - BRAF Inhibitor) - Braftovi PA Policy
Oncology (Oral - BRAF Inhibitor) - Tafinlar PA Policy
Oncology (Oral - BRAF Inhibitor) - Zelboraf PA Policy
Oncology (Oral - Bruton's Tyrosine Kinase Inhibitor) - Brukinsa PA Policy
Oncology (Oral - Bruton's Tyrosine Kinase Inhibitor) - Imbruvica PA Policy
Oncology (Oral - Bruton's Tyrosine Kinase Inhibitor) - Jaypirca PA Policy
Oncology (Oral - Cyclin-Dependent Kinase 4 and 6 Inhibitor) - Ibrance PA Policy
Oncology (Oral - Cyclin-Dependent Kinase 4 and 6 Inhibitor) - Verzenio PA Policy
Oncology (Oral - EGFR Inhibitor) - Erlotinib PA Policy
Oncology (Oral - EGFR Inhibitor) - Gefitinib PA Policy
Oncology (Oral - FMS-Like Tyrosine Kinase 3 Inhibitor) - Rydapt PA Policy
Oncology (Oral - FMS-Like Tyrosine Kinase 3 Inhibitor) - Vanflyta PA Policy
Oncology (Oral - FMS-Like Tyrosine Kinase 3 Inhibitor) - Xospata PA Policy
Oncology (Oral - Hedgehog Pathway Inhibitor) - Erivedge PA Policy
Oncology (Oral - Hedgehog Pathway Inhibitor) - Odomzo PA Policy
Oncology (Oral - Immunomodulator) - Lenalidomide PA Policy
Oncology (Oral - Immunomodulator) - Pomalyst PA Policy
Oncology (Oral - Immunomodulator) - Thalomid PA Policy
Oncology (Oral - Isocitrate Dehydrogenase 1 Inhibitor) - Rezlidhia PA Policy
Oncology (Oral - Isocitrate Dehydrogenase 1 Inhibitor) - Tibsovo PA Policy
Oncology (Oral - MEK Inhibitor) - Cotellic PA Policy
Oncology (Oral - MEK Inhibitor) - Mekinist PA Policy
Oncology (Oral - MEK Inhibitor) - Mektovi PA Policy
Oncology (Oral - Poly [ADP-Ribose] Polymerase Inhibitor) - Akeega PA Policy
Oncology (Oral - Poly [ADP-Ribose] Polymerase Inhibitor) - Lynparza PA Policy
Oncology (Oral - Poly [ADP-Ribose] Polymerase Inhibitor) - Rubraca PA Policy
Oncology (Oral - Poly [ADP-Ribose] Polymerase Inhibitor) - Talzenna PA Policy
Oncology (Oral - Poly [ADP-Ribose] Polymerase Inhibitor) - Zejula PA Policy
Oncology (Oral - Proteasome Inhibitor) - Ninlaro PA Policy
Ophthalmic - Glaucoma - Alpha-Adrenergic Agonists Step Therapy Policy Policy
Ophthalmic - Glaucoma - Beta-adrenergic Blockers Step Therapy Policy Policy
Ophthalmic - Glaucoma - Carbonic Anhydrase Inhibitors Step Therapy Policy Policy
Ophthalmic - Glaucoma - Combination Products Step Therapy Policy Policy
Ophthalmic - Glaucoma - Prostaglandins and Rho Kinase Inhibitors Policy
Ophthalmic - Glaucoma - Prostaglandins and Rho Kinase Inhibitors Step Therapy Policy Policy
Ophthalmic - Glaucoma - Prostaglandins PA Policy Policy
Ophthalmic Anti-Allergics - Mast Cell Stabilizers Step Therapy Policy Policy
Ophthalmic Anti-Allergics - Miscellaneous Step Therapy Policy Policy
Ophthalmic Corticosteroids Step Therapy Policy Policy
Ophthalmic for Dry Eye Disease - Cyclosporine Products PA Policy Policy
Ophthalmic for Dry Eye Disease - Eysuvis PA Policy Policy
Ophthalmic for Dry Eye Disease - Lacrisert PA Policy Policy
Ophthalmic for Dry Eye Disease - Xiidra PA Policy Policy